title: Adverse effects on cardiovascular status and lipid levels of albino Wistar rats treated with cisplatin and oxaliplatin in combination with 5 Fluorouracil.
abstract: The study was designed to comparatively assess direct damages on cardiac tissues and aorta associated with abnormalities in lipid profile and cardiac biomarkers induced by two platinum cytotoxic compounds with and without 5FU (5Fluorouracil) in rats. Albino Wistar rats were treated with 5FU (15mg/kg), cisplatin (0.8mg/kg) and oxaliplatin (0.8mg/kg) in different dosing schedules. The changes in the lipid levels, CPK and Tropinin I levels, following treatment with single and combination schedules of CDDP, 5FU and Oxaliplatin were compared with the control group maintained on normal saline. Changes in LDL and cholesterol levels were highly significant in cisplatin and oxaliplatin treated rats. Myofibrillar loss and vascular wall thickening was seen in cisplatin treatment groups in the acute model of toxicity. The damages were mild but progressive. Tropinin I levels were raised well above diagnostic risk levels in the delayed model of toxicity in the rats treated with oxaliplatin in combination of 5FU, indicative of definite cardiotoxic potential of oxaliplatin in combination of 5FU mimicking the FOLFOX regimen.
authors.affiliation: Department of Pharmacology, University of Karachi, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan.
authors.forename: Rahila
authors.initials: R
authors.lastname: Najam
authors.affiliation: Department of Pharmacology, Ziauddin College of Pharmacy, Ziauddin University, Karachi, Pakistan.
authors.forename: Nusrat
authors.initials: N
authors.lastname: Bano
authors.affiliation: Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: Talat
authors.initials: T
authors.lastname: Mirza
authors.affiliation: -
authors.forename: Saba
authors.initials: S
authors.lastname: Hassan
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D001011:Aorta / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D004334:Drug Administration Schedule; D005355:Fibrosis; D005472:Fluorouracil / Q000008:administration & dosage / Q000633:toxicity; D008055:Lipids / Q000097:blood*; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000633:toxicity; D000077150:Oxaliplatin; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D019210:Troponin I / Q000097:blood; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D008055:Lipids; D009944:Organoplatinum Compounds; D019210:Troponin I; D000077150:Oxaliplatin; D002945:Cisplatin; D005472:Fluorouracil